NCT06229522 Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
| NCT ID | NCT06229522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2037-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-11-16 with a primary completion date of 2037-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. Given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. The aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent form; 2. Female sex; 3. Age ≥18 years; 4. Diagnosis of ovarian cancer; 5. Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose Exclusion Criteria: 1. Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments; 2. Pregnancy or breast-feeding 3. History of concomitant or previous malignancy in the last 5 years
Contact & Investigator
Vincenzo Canzonieri, MD
PRINCIPAL INVESTIGATOR
Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Frequently Asked Questions
Who can join the NCT06229522 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06229522 currently recruiting?
Yes, NCT06229522 is actively recruiting participants. Contact the research team at vcanzonieri@cro.it for enrollment information.
Where is the NCT06229522 trial being conducted?
This trial is being conducted at Aviano, Italy.
Who is sponsoring the NCT06229522 clinical trial?
NCT06229522 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Vincenzo Canzonieri, MD at Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.